Table 3.
Rate of HCV Recurrence post-SVR following DAAs therapy
| Studies | Subgroup | No. of Studies | Pooled Estimate of Recurrence/1000 PYFU (95% CI) | Heterogeneity (I2; P Value) |
|---|---|---|---|---|
| Low-risk HCV mono-infected population | ||||
| All studies | All | 16 | 0.89(0.16–2.03) | 61%; <0.01 |
| Sensitivity analysis | High-quality (NOS≥6) | 14 | 1.22(0.45–2.26) | 54%; <0.01 |
| Subgroups | Recurrence in prospective cohorts | 6 | 1.31(0.61–2.20) | 41%; 0.13 |
| Recurrence in RCTs | 10 | 0.76(0.00–2.64) | 68%; <0.01 | |
| Late relapse | 14 | 0.32(0.00–1.40) | 73%; <0.01 | |
| Reinfection | 14 | 0.06 (0.00–0.32) | 0%; 0.57 | |
| High-risk HCV mono-infected population | ||||
| All studies | All | 19 | 29.37(15.54–46.91) | 90%; <0.01 |
| Sensitivity analysis | High-quality (NOS≥6) | 16 | 28.68(13.21–49.22) | 91%; <0.01 |
| Subgroups | Recurrence in prospective cohorts | 8 | 51.74(16.70–102.78) | 89%; <0.01 |
| Recurrence in RCTs | 4 | 14.21(3.53–30.60) | 59%; 0.06 | |
| Recurrence in retrospective cohorts | 7 | 26.83(7.10–57.70) | 93%; <0.01 | |
| All PWID studies | 15 | 19.65(8.50–34.48) | 85%; <0.01 | |
| All prisoner studies | 4 | 85.89(3.52–258.56) | 94%; <0.01 | |
| Late relapse | 18 | 0.00(0.00–0.00) | 0%; 1.00 | |
| Reinfection | 18 | 25.82(13.08–42.13) | 89%; <0.01 | |
| HIV/HCV coinfected population | ||||
| All studies | All | 8 | 23.25(4.24–53.39) | 88%; <0.01 |
| Sensitivity analysis | High-quality (NOS≥6) | 5 | 13.66(0.48–38.64) | 87%; <0.01 |
| Subgroups | Recurrence in prospective cohorts | 4 | 9.33(0.00–34.55) | 83%; <0.01 |
| Recurrence in retrospective cohorts | 4 | 43.34(8.44–99.15) | 66%; 0.03 | |
| Late relapse | 8 | 0.00(0.00–0.00) | 0%; 0.76 | |
| Reinfection | 8 | 23.25(4.24–53.39) | 88%; <0.01 | |
Abbreviations: NO, number; RCTs, randomized controlled trials; PWID, persons who inject drugs.
Forest Plots of recurrence rates can be found in the Supplementary Appendix (Supplementary Figure. 2A, 2B and 2C).